The S-3 is a contractual resale registration with no new capital raised, but the overhang from up to 2.68M shares that can be sold by Oberland Capital is a near-term headwind, especially with the stock trading below both the $4.48 purchase price and $6.72 conversion price. Monitor for any selling by Oberland and for any additional note tranche issuances that could increase conversion shares.
Price Chart
Executive Summary
Opus Genetics filed an S-3 registration statement to register up to 2,678,570 shares of common stock for resale by selling stockholders (Oberland Capital entities). The shares consist of 1,116,070 shares already issued at $4.48/share and up to 1,562,500 shares issuable upon conversion of up to 10% of the principal amount of $105M in convertible notes (conversion price $6.72). The company receives no proceeds from this resale registration, which fulfills a contractual covenant from the April 2026 Stock Purchase and Conversion Agreement. The filing itself is a routine contractual shelf registration, but the context of a recent $35M note tranche issuance and the company's pre-revenue clinical-stage status with a $378M market cap creates overhang risk.
Key Financial Metrics
Key Facts
- Registers up to 2,678,570 shares for resale by selling stockholders (Oberland Capital entities)
- Includes 1,116,070 shares already issued at $4.48/share and up to 1,562,500 shares issuable upon note conversion at $6.72/share
- Notes have aggregate committed principal amount of up to $105M; first tranche of $35M issued April 21, 2026
- Company receives no proceeds from this resale registration
- Stock closed at $4.12 on June 1, 2026, below the $4.48 purchase price and well below the $6.72 conversion price
- 82,565,835 shares outstanding as of May 31, 2026; potential dilution from this registration is ~3.2% of current shares
- Company is a clinical-stage biopharma with no significant revenue and expects continued losses
Financial Impact
Up to 2,678,570 shares registered for resale, representing ~3.2% dilution relative to current 82.6M shares outstanding. At $4.12/share (June 1 close), the registered shares have a market value of ~$11M.
Risk Factors
- Resale of registered shares by Oberland Capital could pressure the stock price
- Stock trading at $4.12 is below the $4.48 purchase price and well below the $6.72 conversion price, suggesting potential further downside
- Company is pre-revenue with ongoing losses and will need additional capital, potentially through further dilutive offerings
- Additional note tranches (up to $105M total) could increase conversion shares beyond the 1.56M registered here
- Massive existing overhang from 21.15M warrants, 16.01M pre-funded warrants, and 7.89M stock options
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001140361-26-024283 |
| Document: ny20075388x1_ex107.htm | 0001140361-26-024283 |
| Document: ny20075388x1_ex5-1.htm | 0001140361-26-024283 |
| Document: ny20075388x1_ex23-1.htm | 0001140361-26-024283 |
| Document: 0001140361-26-024283-index-headers.html | 0001140361-26-024283 |
| Document: 0001140361-26-024283-index.html | 0001140361-26-024283 |
| Document: 0001140361-26-024283.txt | 0001140361-26-024283 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 27, 2026 today | Insider Cluster | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 23, 2026 4d ago | 144 | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 21, 2026 6d ago | 8-K | $3.82 | awaiting T+60 | — | $3.46 (−9.42%) |
Oct 15, 2026 12d ago | 8-K | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Oct 15, 2026 12d ago | Press Release | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Sep 22, 2026 5w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.46 (−32.95%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.46 (−42.72%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.46 (−39.62%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.46 (−22.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers